Breaking Down Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. Financial Health: Key Insights for Investors

From its founding in April 2009 to its STAR Market listing in May 2021 under ticker 688076, Sinopep-Allsino Biopharmaceutical has evolved into a vertically integrated CDMO/CMO powerhouse-employing 2,028 people as of December 2024 (a 31.26% year-on-year headcount jump)-that reported revenue of CNY 1.62 billion in 2024 (up 57.21%) and net income of CNY 404.39 million (up 148.19%), while generating roughly CNY 819,570 per employee; its two modern bases in Lianyungang and Jiande have cleared three U.S. FDA cGMP on-site inspections, the Lianyungang site secured Brazil ANVISA CBPF‑GMP certification in August 2025 and both sites earned EcoVadis Bronze in September 2025, even as the company faced a July 2025 regulatory setback with a CNY 47.4 million fine and delisting warning (and an CNY 18 million fine for actual controller Zhao Dezhong)-positioning Sinopep-Allsino as a major API supplier for GLP‑1 and weight‑loss therapeutics with deep R&D investment (>10% of revenue), provincial R&D centers and high‑profile scientific collaborations that underpin its growth, compliance and commercial model.}

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS) - Intro

• Founding: April 2009 - core focus on peptide and small‑molecule drug R&D, production and sales.
• IPO: Listed on Shanghai STAR Market in May 2021 (ticker: 688076.SS).
• Workforce: 2,028 employees as of December 2024, a 31.26% increase year‑on‑year.
• Regulatory/Compliance events:
  • July 2025: CNY 47.4 million fine by CSRC for inflated financial results; delisting warning issued.
  • August 2025: Lianyungang facility received ANVISA CBPF‑GMP certification (Brazil).
  • September 2025: Jiande and Lianyungang facilities awarded EcoVadis Bronze Medal Certification.

• Drug discovery and in‑house R&D to develop peptide and small‑molecule candidates.
• Clinical development partnerships and licensing deals (out‑licensing of assets or co‑development).
• Manufacturing and commercial sale of approved peptide and small‑molecule products through domestic and selected international channels.
• Contract manufacturing services leveraging GMP‑certified facilities (e.g., ANVISA CBPF‑GMP supports exports to Brazil/Latin America).
• Revenue streams typically include product sales, milestone and royalty payments from collaborations, and contract manufacturing fees.

• Manufacturing footprint: Multiple production sites (notably Jiande and Lianyungang) with increasing emphasis on international compliance and sustainability after 2025 certifications.
• Regulatory risk: CSRC enforcement action in July 2025 (CNY 47.4M fine) raises material governance and market‑access considerations-delisting remains a key risk until resolved.
• Human capital: Rapid workforce growth (31.26% YoY to 2,028 by Dec 2024) reflects scale‑up of R&D and manufacturing capacity but implies increased cost base.

• Ticker: 688076.SS (Shanghai STAR Market).
• Further company profile and timeline: Sinopep-Allsino Bio Pharmaceutical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS): History

• Listing: STAR Market, Shanghai Stock Exchange (ticker 688076.SS)
• Workforce: 2,028 employees (as of December 2024)
• Shareholder base: mix of institutional and retail investors

• Major governance risk: delisting warning from CSRC (July 2025)
• Controller-level penalty: CNY 18 million against Zhao Dezhong
• Corporate scale: operational headcount supporting R&D and manufacturing (2,028 staff)

• R&D and clinical development: discovery and development of peptide/biologic candidates
• Manufacturing and CMO services: production for internal programs and third-party supply
• Licensing and partnerships: out-licensing or co-development deals for late-stage assets
• Commercial sales: revenue from approved products and contracted manufacturing

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS): Ownership Structure

• Mission: Drive technological innovation to resolve key difficulties in drug R&D/production and deliver green, low-cost, high-quality, efficient pharmaceutical products and technical services worldwide.
• Core values: technology-first R&D, sustainability in manufacturing, cost-efficiency, and global collaboration.

• R&D intensity: Company policy commits to investing over 10% of annual revenue in research and development to accelerate pipeline and platform advances.
• R&D infrastructure: Three provincial-level R&D centers-Sinopep Biology, Allsino, and Simbospharm-support discovery, process development, and formulation work.
• Talent & collaboration: Strategic partnerships with international experts (including Nobel laureate Professor Hartmut Michel) to accelerate technological breakthroughs and platform validation.

• Designations: Identified as a National High-tech Enterprise and awarded provincial-level science & technology enterprise honors, reflecting compliance with innovation and IP standards.

• R&D-driven product development: Internal pipeline and custom development services for domestic and international pharma clients.
• Manufacturing & tech services: Green process technologies aimed at reducing cost and environmental footprint while ensuring quality and scale-up capabilities.
• Collaborative licensing & partnerships: Co-development and licensing arrangements leveraging in-house platforms and external expert networks.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS): Mission and Values

• Core mission: deliver compliant, high-quality small-molecule APIs and finished dosage forms to global customers.
• Values: regulatory excellence, vertical integration, sustainable operations, customer partnership.

• Two modern production bases: Lianyungang (Jiangsu Province) and Jiande (Zhejiang Province).
• Service offering: CDMO and CMO services focused on small-molecule chemical APIs and downstream dosage forms.
• Regulatory track record: facilities have passed U.S. FDA cGMP on-site inspections three times.
• International certifications: Lianyungang facility received the CBPF-GMP certificate from Brazil's ANVISA in August 2025.
• Sustainability: awarded EcoVadis Bronze Medal Certification in September 2025 for corporate sustainability performance.

• CDMO project revenue - fees for development, process transfer, scale-up and regulatory documentation for customer-owned molecules.
• CMO and contract supply - long-term supply contracts for APIs and finished dosage forms, often tiered by volume and milestone payments.
• Own-label generics and private-label finished products - revenue from internally manufactured generic APIs and formulations sold to domestic and export markets.
• Regulatory-enabled market access premium - higher pricing/market share for production sites with FDA, ANVISA and other international approvals.

• Target customers: multinational pharma, regional generics manufacturers, biotech firms needing commercial API supply and fill/finish services.
• Contract structure: mix of one-off development fees, multi-year supply agreements, and capacity reservation arrangements to stabilize throughput and cash flow.
• Value proposition: regulated-site manufacturing, repeatable FDA inspection success, and end-to-end capability reduce time-to-market risk for customers.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS): How It Works

• Core product lines: peptides, small-molecule APIs, oligonucleotides.
• Intermediates: fulvestrant, oseltamivir and other high-value intermediates supplied to pharmaceutical manufacturers.
• Service offerings: CDMO (research & development, process development) and CMO (commercial manufacturing) for external clients.

• Direct sales of APIs and intermediates to pharmaceutical companies and distributors.
• Contract manufacturing (CMO) for third parties-commercial-scale API production under long-term or project contracts.
• Contract development and manufacturing (CDMO) services-custom synthesis, process scale-up, and analytical support billed per project or milestone.
• Specialty/custom peptide and oligonucleotide projects commanding premium pricing and recurring service fees.

• Vertical integration from R&D to commercial production reduces COGS and shortens time-to-market for customers.
• Flexible multi-purpose production lines enable switching between peptide, small-molecule, and oligonucleotide runs to optimize utilization.
• Quality and regulatory compliance (GMP) enable supply contracts with multinational and domestic pharma firms.

• Strong demand for peptide and oligonucleotide APIs and tailored CDMO projects drove revenue growth to CNY 1.62 billion in 2024 (up 57.21% YoY).
• Operating leverage and margin expansion supported net income of CNY 404.39 million in 2024 (up 148.19% YoY).
• Revenue per employee of approximately CNY 819,570 indicates higher productivity and utilization across R&D and manufacturing staff.

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. (688076.SS): How It Makes Money

• Core revenue streams: commercial API sales, contract manufacturing & development (CMDO), technology transfer and licensing fees, and specialized intermediates for peptide drugs.
• Customer base: long-term partnerships with multinational pharmaceutical corporations and biotechnology companies provide recurring revenue and demand visibility.
• Strategic focus: R&D-driven product portfolio expansion (new peptide APIs and synthetic routes) to capture higher-margin specialty products.

• Market position & outlook: Positioned as a top-tier API supplier for GLP‑1 therapies with growing international compliance (e.g., ANVISA CBPF‑GMP) and sustainability credentials (EcoVadis Bronze), while regulatory remediation following the CNY 47.4 million fine is a near-term risk.
• Profit drivers: securing long-term supply contracts, migrating customers to in-house supply for clinical-to-commercial scale, and premium pricing on complex peptide APIs.
• Risks: regulatory/financial penalties, customer concentration, and raw-material supply volatility affecting margins and access to capital.